Prophylaxis of contrast material-induced nephropathy in patients in intensive care: Acetylcysteine, theophylline, or both? A randomized study

Radiology

Volumn 239, Issue 3, 2006, Pages 793-804

  Huber, Wolfgang ^a   Eckel, Florian ^a   Hennig, Michael ^a   Rosenbrock, Hilkea ^a   Wacker, Annette ^b   Saur, Dieter ^a   Sennefelder, Angelika ^a   Hennico, Romain ^a   Schenk, Cordula ^a   Meining, Alexander ^a   Schmelz, Renate ^a   Fritsch, Ralph ^a   Weiss, Wolfgang ^b   Hamar, Peter ^c   Heemann, Uwe ^a   Schmid, Roland M ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALBUMIN; ALPHA 1 MICROGLOBULIN; BETA N ACETYLGALACTOSAMINIDASE; CONTRAST MEDIUM; CREATININE; IOMEPROL; PROTEIN; THEOPHYLLINE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; CLINICAL TRIAL; CONTRAST RADIOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FEMALE; HEART ARRHYTHMIA; HUMAN; INTENSIVE CARE UNIT; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; STATISTICAL SIGNIFICANCE;

ACETYLCYSTEINE; ADULT; AGED; AGED, 80 AND OVER; BLOOD UREA NITROGEN; CONTRAST MEDIA; CREATININE; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; FREE RADICAL SCAVENGERS; HUMANS; INTENSIVE CARE; IOPAMIDOL; KIDNEY DISEASES; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PROSPECTIVE STUDIES; PROTECTIVE AGENTS; RISK FACTORS; THEOPHYLLINE; TIME FACTORS;

EID: 33744811961     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2393041456     Document Type: Review

References (48)

1. Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983;74:243-248.
2. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-375.
3. Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989;86:649-652.
4. Rich MW, Crecelius CA. Incidence, risk factors and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years and older. Arch Intern Med 1990;150:1237-1242.
5. Huber W, Ilgmann K, Page M, et al. Effect of theophylline on contrast material-induced nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology 2002;223:772-779.
6. Huber W, Schipek C, Ilgmann K, et al. Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol 2003;91:1157-1162.
7. Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990;89:615-620.
8. 1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? Nephrol Dial Transplant 2000;13:43-49.
9. Tepel M, van der Giet M, Schwarzfeld C, Laufer LJ, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-184.
10. Barrett BJ, Parfrey PS. Prevention of nephrotoxicity induced by radiocontrast agents. N Engl J Med 1994;331:1449-1450.
11. Abizaid AS, Clark CE, Mintz GS, et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 1999;83:260-263.
12. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality: a cohort analysis. JAMA 1996;275:1489-1494.
13. Eisenberg RL, Bank WO, Hedgock MW. Renal failure after major angiography can be avoided with hydration. AJR Am J Roentgenol 1981;136:859-861.
14. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast-media associated nephropathy: randomized comparison of 2 hydration regimes in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:329-336.
15. Trivedi HS, Moore H, Nasr S, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephropathy. Nephron Clin Pract 2003;93:C29-C34.
16. Erley CM, Duda SH, Schlepckow S, et al. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int 1994;45:1425-1431.
17. Huber W, Jeschke B, Page M, et al. Reduced incidence of radio-contrast induced nephropathy in ICU patients under theophylline prophylaxis. Intensive Care Med 2001; 27:1200-1209.
18. Kapoor A, Kumar S, Gulati S, Gambhir S, Sethi RS, Sinha N. The role of theophylline in contrast-induced nephropathy: a case-control study. Nephrol Dial Transplant 2002;17:1936-1941.
19. Ix JH, McCulloch CE, Chertow GM. Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. Nephrol Dial Transplant 2004;19:2747-2753.
20. Shyu KG, Cheng JJ, Peiliang K. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002;40:1383-1388.
21. Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention. JAMA 2003; 289:553-558.
22. Diaz-Sandoval IJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002;89:356-358.
23. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 2003;41:2114-2118.
24. Briguori C, Manganelli F, Scarpato P, et, al. Acetylcysteine and contrast-agent-associated nephrotoxicity. J Am Coll Cardiol 2002; 40:298-303.
25. Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial on N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 2002;62:2202-2207.
26. Allaqaband S, Tumuluri R, Malik AM, et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002;57:279-283.
27. Boccalandro F, Amhad M, Smalling RW, Sdringola S. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv 2003;58:336-341.
28. Vallero A, Cesano G, Pozzato M, et al. Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC) [in Italian]. G Ital Nefrol 2002;19:329-533.
29. Fung JW, Szeto CC, Chan WW, et al. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. Am J Kidney Dis 2004;43:801-808.
30. Goldenberg I, Shechter M, Matetzky S, et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography: a randomized controlled trial and review of the current literature. Eur Heart J 2004;25:212-218.
31. Nallamothu BK, Shojania KG, Saint S, et al. Is acetylcysteine effective in preventing contrast-related nephropathy? a meta-analysis. Am J Med 2004;117:938-947.
32. Azmus AD, Gottschall C, Manica A, et al. Effectiveness of acetylcysteine in prevention of contrast nephropathy. J Invasive Cardiol 2005;17:80-84.
33. Touati C, Idee JM, Deray G. Modulation of the renal effects of contrast media by endothelium derived nitric oxide in the rat. Invest Radiol 1993;28:814-820.
34. Lund G, Einzig S, Rysavy J, Salomonowitz E, Castaneda-Zuniga W, Amplatz K. Effect of prostaglandin inhibition on the renal vascular response to ionic and non-ionic contrast media in the dog. Acta Radiol Diagn (Stockh) 1984;25:407-410.
35. Oldroyd S, Slee SJ, Haylor J, Morcos SK, Wilson C. Role for endothelin in the renal responses to radiocontrast media in the rat. Clin Sci (Lond) 1994;87:427-434.
36. Osswald H, Schmitz HJ, Kemper R. Tissue content of adenosine, inosine and hypoxanthine in the rat kidney after ischemia and postischemic recirculation. Pflugers Arch 1977;371:45-49.
37. Arakawa K, Suzuki H, Naitoh M, et al. Role of adenosine in the renal responses to contrast media. Kidney Int 1996;49:1199-1206.
38. Oldroyd SD, Fang L, Haylor JL, Yates MS, El Nahas AM, Morcos SK. Effects of adenosine receptor antagonists on the responses to contrast media in the isolated rat kidney. Clin Sci 2000;98:303-311.
39. Erley CM, Duda SH, Rehfuss D, et al. Prevention of radiocontrast-media- induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transplant 1999;14:1146-1149.
40. Katholi RE, Taylor GJ, McCann WP, et al. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 1995;193:17-22.
41. Kolonko A, Wiecek A, Kokot F. The nonselective adenosine antagonist does prevent renal dysfunction induced by radiographic contrast agents. J Nephrol 1998;11:151-156.
42. Yoshioka T, Fogo A, Beckman JK. Reduced activity of antioxidant enzymes underlies contrast-media-induced renal injury in volume depletion. Kidney Int 1992;41:1008-1015.
43. Baliga R, Ueda N, Walker PD, Shah SV. Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis 1997;29:465-477.
44. Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol 1990;258(1 pt 2):F115-F120.
45. DiMari J, Megyesi J, Udvarhelyi N, Price P, Davis R, Safirstein R. N-acetylcysteine ameliorates ischemic renal failure. Am J Physiol 1997;272(3 pt 2):F292-F298.
46. Katholi RE, Woods WT, Taylor GJ, et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis 1998;32:64-71.
47. Hoffmann U, Fischereder M, Krüger B, Drobnik W, Krämer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004;15:407-410.
48. Genet S, Kale RK, Baquer NZ. Effects of free radicals on cytosolic creatinine kinase activities and protection by antioxidant enzymes and sulfhydryl compounds. Mol Cell Biochem 2000;210:23-28.